Looking for Innovative Small-Cap Biotech Companies: George Zavoico InvestorIdeas.com (press release) It was up against Rituxan (rituximab; from Genentech) a hugely successful drug. But Zevalin, I think, has a number of advantages-including cost and efficacy-over Rituxan, and it just remains to be seen how well Spectrum will be able to educate ... |
